Literature DB >> 21993404

Comparison of three-dimensional versus intensity-modulated radiotherapy techniques to treat breast and axillary level III and supraclavicular nodes in a prone versus supine position.

Rajni A Sethi1, Hyun Soo No, Gabor Jozsef, Jane P Ko, Silvia C Formenti.   

Abstract

BACKGROUND AND
PURPOSE: To determine the optimal method of targeting breast and regional nodes in selected breast cancer patients after axillary dissection, we compared the results of IMRT versus no IMRT, and CT-informed versus clinically-placed fields, in supine and prone positions.
MATERIALS AND METHODS: Twelve consecutive breast cancer patients simulated both prone and supine provided the images for this study. Four techniques were used to target breast, level III axilla, and supraclavicular fossa in either position: a traditional three-field three-dimensional conformal radiotherapy (3DCRT) plan, a four-field 3DCRT plan using a posterior axillary boost field, and two techniques using a CT-informed target volume consisting of an optimized 3DCRT plan (CT-planned 3D) and an intensity-modulated radiotherapy (IMRT) plan. The prescribed dose was 50 Gy in 25 fractions.
RESULTS: CT-planned 3D and IMRT techniques improved nodal PTV coverage. Supine, mean nodal PTV V50 was 50% (3-field), 59% (4-field), 92% (CT-planned 3D), and 94% (IMRT). Prone, V50 was 29% (3-field), 42% (4-field), 97% (CT-planned 3D), and 95% (IMRT). Prone positioning, compared to supine, and IMRT technique, compared to 3D, lowered ipsilateral lung V20.
CONCLUSIONS: Traditional 3DCRT plans provide inadequate nodal coverage. Prone IMRT technique resulted in optimal target coverage and reduced ipsilateral lung V20.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21993404     DOI: 10.1016/j.radonc.2011.09.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

Authors:  Carolyn Taylor; Candace Correa; Frances K Duane; Marianne C Aznar; Stewart J Anderson; Jonas Bergh; David Dodwell; Marianne Ewertz; Richard Gray; Reshma Jagsi; Lori Pierce; Kathleen I Pritchard; Sandra Swain; Zhe Wang; Yaochen Wang; Tim Whelan; Richard Peto; Paul McGale
Journal:  J Clin Oncol       Date:  2017-03-20       Impact factor: 44.544

2.  Pilot study of feasibility and dosimetric comparison of prone versus supine breast radiotherapy.

Authors:  E Fernández-Lizarbe; A Montero; A Polo; R Hernanz; R Morís; S Formenti; A Ramos
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

3.  Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer.

Authors:  Minji Koh; Jinhong Jung; Su Ssan Kim; Seung Do Ahn; Eun Kyung Choi; Il Yong Chung; Jong Won Lee; Sung-Bae Kim; Jae Ho Jeong
Journal:  Breast Cancer Res Treat       Date:  2021-04-23       Impact factor: 4.872

4.  A dosimetric and radiobiological evaluation of VMAT following mastectomy for patients with left-sided breast cancer.

Authors:  Yun Zhang; Yuling Huang; Shenggou Ding; Xingxing Yuan; Yuxian Shu; Jinhui Liang; Qingfeng Mao; Chunling Jiang; Jingao Li
Journal:  Radiat Oncol       Date:  2021-09-06       Impact factor: 3.481

5.  Hybrid volumetric-modulated arc therapy for postoperative breast cancer including regional lymph nodes: the advantage of dosimetric data and safety of toxicities.

Authors:  Yoshiko Doi; Minoru Nakao; Hideharu Miura; Shuichi Ozawa; Masahiro Kenjo; Yasushi Nagata
Journal:  J Radiat Res       Date:  2020-09-08       Impact factor: 2.724

6.  The role of a prone setup in breast radiation therapy.

Authors:  Nelly Huppert; Gabor Jozsef; Keith Dewyngaert; Silvia Chiara Formenti
Journal:  Front Oncol       Date:  2011-10-11       Impact factor: 6.244

7.  Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study.

Authors:  Maria Cristina Leonardi; Matteo Pepa; Simone Giovanni Gugliandolo; Rosa Luraschi; Sabrina Vigorito; Damaris Patricia Rojas; Maria Rosa La Porta; Domenico Cante; Edoardo Petrucci; Lorenza Marino; Giuseppina Borzì; Edy Ippolito; Maristella Marrocco; Alessandra Huscher; Matteo Chieregato; Angela Argenone; Luciano Iadanza; Fiorenza De Rose; Francesca Lobefalo; Francesca Cucciarelli; Marco Valenti; Maria Carmen De Santis; Anna Cavallo; Francesca Rossi; Serenella Russo; Agnese Prisco; Marika Guernieri; Roberta Guarnaccia; Tiziana Malatesta; Ilaria Meaglia; Marco Liotta; Paola Tabarelli de Fatis; Isabella Palumbo; Marta Marcantonini; Sarah Pia Colangione; Emilio Mezzenga; Sara Falivene; Maria Mormile; Vincenzo Ravo; Cecilia Arrichiello; Alessandra Fozza; Maria Paola Barbero; Giovanni Battista Ivaldi; Gianpiero Catalano; Cristiana Vidali; Cynthia Aristei; Caterina Giannitto; Eleonora Miglietta; Antonella Ciabattoni; Icro Meattini; Roberto Orecchia; Federica Cattani; Barbara Alicja Jereczek-Fossa
Journal:  Br J Radiol       Date:  2021-04-21       Impact factor: 3.629

8.  Modified Volumetric Modulated Arc Therapy in Left Sided Breast Cancer After Radical Mastectomy With Flattening Filter Free Versus Flattened Beams.

Authors:  Youqun Lai; Yanyan Chen; Sangang Wu; Liwan Shi; Lirong Fu; Huiming Ha; Qin Lin
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

9.  Body mass index and patient CT measurements as a predictor of benefit of intensity-modulated radiotherapy to the supraclavicular fossa.

Authors:  Vicky Koh; Johann I Tang; Bok Ai Choo; Chek Wee Tan; Boon Keat Lim; Liang Shen; Jiade Jay Lu
Journal:  Onco Targets Ther       Date:  2013-11-21       Impact factor: 4.147

10.  Radiation dose to the nodal regions during prone versus supine breast irradiation.

Authors:  Melinda Csenki; Dóra Ujhidy; Adrienn Cserháti; Zsuzsanna Kahán; Zoltán Varga
Journal:  Ther Clin Risk Manag       Date:  2014-05-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.